Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $360.3 million.

  • Stoke Therapeutics' Liabilities and Shareholders Equity rose 2282.33% to $360.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 3756.19%. This contributed to the annual value of $271.6 million for FY2024, which is 1892.47% up from last year.
  • Stoke Therapeutics' Liabilities and Shareholders Equity amounted to $360.3 million in Q3 2025, which was up 2282.33% from $384.5 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Liabilities and Shareholders Equity peaked at $406.9 million during Q1 2025, and registered a low of $205.2 million during Q1 2024.
  • For the 4-year period, Stoke Therapeutics' Liabilities and Shareholders Equity averaged around $292.5 million, with its median value being $281.8 million (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 2718.78% in 2024, then surged by 9830.59% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $256.1 million in 2022, then dropped by 10.83% to $228.3 million in 2023, then rose by 18.92% to $271.6 million in 2024, then skyrocketed by 32.67% to $360.3 million in 2025.
  • Its Liabilities and Shareholders Equity was $360.3 million in Q3 2025, compared to $384.5 million in Q2 2025 and $406.9 million in Q1 2025.